SCFAs, butyrate provides the primary energy source for the colonic epithelium, with 60-80% undergoing metabolism.45 The colonocyte's dependence on SCFA metabolism increases from the proximal to the distal colon. 6 Butyrate also regulates epithelial proliferation and differentiation of the colonic mucosa.3 [7] [8] [9] In addition, SCFAs stimulate sodium and fluid salvage by the colon. [1] [2] [3] A growing body of evidence links deficiency, decreased absorption, and impaired metabolism of SCFAs to the pathophysiology of multiple types of diarrhoeal disease. Clinical findings suggest SCFA deficiency causes diversion colitis, an inflammatory reaction of the colorectum that occurs after surgical diversion of the colonic contents.'0 Daily colonic perfusion with SCFAs stimulates both clinical and endoscopic remission of diversion colitis after only two weeks. Relapse can be prevented for prolonged periods with continued SCFA treatment.'0 An acute infectious ileocolitis inhibits both SCFA stimulated electrolyte absorption and absorption of physiological concentrations of SCFAs in the rabbit. These transport abnormalities are associated with increased luminal concentrations of SCFAs. 1 " Ulcerative colitis inhibits both in vivo and in vitro SCFA oxidation by colonic epithelial cells.'2-'4 Furthermore, in the rat, metabolic inhibition of colonic epithelial SCFA oxidation causes colitis.'5 Despite evidence for impaired SCFA oxidation in distal ulcerative colitis, enema therapy with combinations of SCFAs has been used successfully to treat this disease. '6 17 Furthermore, two clinical studies showed that enema therapy with 80-100 m1M butyrate as the sole SCFA, stimulated clinical, endoscopic, and histological improvement in patients with refractory distal ulcerative colitis. '8 19 Because of the success of butyrate enema therapy in distal ulcerative colitis, the aims of these experiments were: (a) to examine the effects of a chronic experimental colitis on in vitro SCFA stimulated electrolyte absorption; (b) to correlate changes in transport with other parameters of colonic damage and inflammation; and (c) to assess the effects of treatment with daily butyrate enemas given in a pharmacological concentration (100 mM) on recovery of colonic structure and function. Experimental colitis was induced in rats with trinitrobenzenesulphonic acid (TNBS) and the resulting injury was examined for a short (five days) and a long (24 performed, all TNBS treated rats had persistent diarrhoea and developed significant (p<0001) weight loss (-7 (2) g) compared with the weight gain (31 (5)) seen in controls. Diarrhoea persisted in most animals with TNBS colitis that received either no treatment (7 of 9) or 19 days of saline enemas (7 of 8). In contrast by day 24, diarrhoea ceased in seven of eight animals with TNBS colitis that were treated with butyrate enemas for 19 days. No diarrhoea was seen throughout the study period in controls that received no treatment or 19 days of either saline or butyrate enemas.
Weight gain from day 5 to 23 did not differ between the untreated (137 (11) g, n=9) , saline enema treated (120 (8), n=7) or butyrate enema treated (130 (7), n=6) control groups. The weight gains of the untreated (73 (11) g, n=9) and saline enema treated (72 (10), n=8) groups with TNBS colitis were significantly decreased (p<0-01) compared with their respective control groups. In contrast, the weight gain (98 (9) g, n=8) from day 5 to 23 of the butyrate enema treated TNBS group recovered to that of control groups.
Colonic damage score In all groups of controls examined, either on day 5 (n=10) or day 23 (n=22), no colonic damage was seen and colonic damage score was zero. Colonic damage scores of rats with TNBS colitis, including the untreated group examined on day five (10-0 (0 7), n=8) as well as the untreated (8.0 (0.8)) and saline enema treated (7-8 (0.6)) groups examined on day 24, were significantly higher (p<0.01) compared with the butyrate enema treated TNBS group examined on day 24 (3.7 (0.6)). Two animals in the butyrate enema treated TNBS group displayed focal hyperaemia of the colon and in six rats, one small area of ulceration was seen, associated with a minor adhesion in three. Severity of colonic damage did not differ between the untreated TNBS colitis group examined on day five and either the untreated or the saline enema treated TNBS colitis groups evaluated on day 24 of the study. Ulcers in these three groups were increased both in number and size compared with the butyrate enema treated TNBS group. Also, both minor and major adhesions were seen.
Tissue MPO activity Tissue MPO activities of the respective control groups were all less than 3 units/mg tissue and did not differ between treatment groups (Fig 1) . On day five of the study, colonic MPO activity was significantly increased (p<0001) in the TNBS group compared with untreated controls (Fig 1) . On day 24 of the study, colonic MPO activities in the untreated and the saline enema treated TNBS groups were significantly decreased (p<0.01) compared with the TNBS group on day five, but remained significantly increased (p<0-01) compared with values of their respective control groups on day 24 (Fig 1) . In contrast with the persistent increases in tissue MPO the addition of butyrate, confirming elec-_ troneutral stimulation of Na+ absorption.
Similarly, in the control groups on day 24 that received either daily saline or SCFA enemas from day 5 to 23 and were not subjected to TNBS colitis, the addition of butyrate stimulated Jms and Jnet Na+ fluxes above basal activ-6) ities and did not change Jsm Na+ flux, ISc or G 4) (Table II) . In contrast, the distal colons of both the day 5 and day 24 untreated groups with ) TNBS colitis as well as the day 24 saline enema treated group failed to show stimulation of Jms or Jnet Na+ absorption after the 3) 4) addition of 25 mM butyrate (Table II) .
Jsm Na+ flux and G in these three groups and 2) Isc in the day 5 and day 24 untreated TNBS 5) colitis groups were not changed after the addition of butyrate. Also on day five, TNBS (Table II) .
Similar to the findings in the control groups, Jsm Na+ flux, Isc or G did not differ between the .e basal and stimulated periods in the butyrate O enema treated TNBS group on day 24. S An examination of A Jnet Na+ transport sum-). marises these data (Fig 2) . The addition of butyrate to the distal colon of all control groups stimulated A Jnet Na+ absorption above basal values to a similar degree (Fig 2) . Na+ al absorption was replaced by mild Na+ secretion ys after the addition of butyrate to the mucosa of ns the day five untreated, the day 24 untreated, id and the day 24 saline enema treated groups c-with TNBS colitis (Fig 2) . In contrast in the )y day 24 butyrate enema treated TNBS colitis group, the addition of a physiological concentration of butyrate once against stimulated A Jnet Na+ absorption to values similar to those seen in all control groups not subjected to TNBS colitis.
Discussion
In these in vitro experiments, the addition of a physiological concentration of butyrate (25 mM) to the mucosal side of the distal rat colon of untreated controls stimulated electroneutral Na+ absorption, confirming previous findings -of Binder and 
